title: Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children.
abstract: The immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine (Epaxal®) was evaluated in a group of 45 Thai children with human immunodeficiency virus (HIV) infection, age 2-16 years. Vaccines were administered at 0 and 6 months. Anti-HAV antibody titers were measured at baseline (before injection) 1 and 7 months after primary vaccination. The prevalence of HAV protective antibody in 45 Thai HIV-infected children was 13.6%. The seroprotection rate was 71% at 1 month and 100% at 7 months. The booster dose increased geometric mean concentration (GMC) from 106.5 mIU/ml to 3486.1 mIU/ml. Higher CD4 lymphocyte counts at enrollment was a predictive factor for HAV antibody response. Both doses of Epaxal® were well tolerated. These preliminary data suggest that a pediatric dose of Epaxal® is an effective hepatitis A vaccine for HIV-infected children and should be considered for implementation on a larger scale in the pediatric HIV population.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Rama 4 Road, Pratumwan, Bangkok 10330, Thailand.
authors.forename: Rachanee
authors.initials: R
authors.lastname: Saksawad
authors.forename: Sasithorn
authors.initials: S
authors.lastname: Likitnukul
authors.forename: Boonyarat
authors.initials: B
authors.lastname: Warachit
authors.forename: Orrawadee
authors.initials: O
authors.lastname: Hanvivatvong
authors.forename: Yong
authors.initials: Y
authors.lastname: Poovorawan
authors.forename: Panitchaya
authors.initials: P
authors.lastname: Puripokai
mesh_terms: D000293:Adolescent; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D007114:Immunization / Q000379:methods; D007117:Immunization, Secondary / Q000379:methods; D008297:Male; D013785:Thailand; D022721:Vaccines, Virosome / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D022721:Vaccines, Virosome; C530970:epaxal berna